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The objective of this study to design a delivery system resistant to the gastrointestinal environment for oral vaccine against porcine
rotavirus. Lactococcus lactis NZ9000 was transformed with segments of vP4 of the porcine rotavirus inserted into the pNZ8112
surface-expression vector, and a recombinant L. lactis expressing VP4 protein was constructed. An approximately 27kDa VP4
protein was conﬁrmed by SDS-PAGE, Western blot and immunostaining analysis. BALB/c mice were immunized orally with
VP4-expression recombinant L. lactis and cellular, mucosal and systemic humoral immune responses were examined. Speciﬁc
anti-VP4 secretory IgA and IgG were found in feces, ophthalmic and vaginal washes and in serum. The induced antibodies
demonstrated neutralizing eﬀects on porcine rotavirus infection on MA104 cells. Our ﬁndings suggest that oral immunization
with VP4-expressing L. lactis induced both speciﬁc local and systemic humoral and cellular immune responses in mice.
1.Introduction
Rotavirus is an important pathogen that causes diarrhea
in human infants and in animals worldwide [1]. Rotavirus
infections in pigs seriously impact the pork industry. The
mortality rate in piglets is extremely variable, ranging from
0 to 50%, and is usually of the order of 0–10%; however, the
loss in growth in recovered piglets is economically the most
important eﬀect of the disease.
Rotaviruses are classiﬁed in the genus rotavirus, in the
family reoviridae. There are three groups of rotaviruses that
aﬀect humans and animals, which are referred to as group
A, B, and C on the basis of the group-speciﬁc inner capsid
protein VP6 [2]. Group A rotaviruses are the most common
agents that cause diarrheal disease in the young of not only
humans but also many animal species including piglets. The
core of porcine rotavirus is composed of double-stranded
RNA arranged in 11 genome segments. Segment 4 encodes
VP4 outer capsid protein on the rotavirus surface, which
not only deﬁnes viral P serotypes, but is also a potent
protective immunogen [3]; VP4 protein can independently
elicit neutralizing antibodies resulting in protective immu-
nity. The antigenic functional region from the 5  end of VP4
is encoded by a 756-bp fragment that includes the trypsin
region of VP8 at the C terminus and VP5 at the N terminus
[4].
Gut mucosal infection occurs primarily by the inva-
sion route via viral replication at the tips of the villi of
epithelial cells in the small intestine, leading to structural
and functional changes in the epithelium. The diarrhea
that results is caused by the multiple activities of the
virus. Malabsorption is a generally accepted mechanism of
rotavirus-induced diarrhea, which is characterized by viral
replication in villus enterocytes in the small intestine, with
subsequent cell lysis and attendant villus blunting, depressed
level of mucosal disaccharidase, watery diarrhea, and dehy-
dration [5, 6]. The rotavirus nonstructural protein NSP4,
which has recently been suggested to have a toxin-like func-
tion, may participate in inducing intestinal inﬂammation
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Because rotaviruses are enteric pathogens, gut mucosal
immune responses are likely to play an important role
in protective immunity against rotavirus infection. Gut
innate immunity provides the ﬁrst line of defense against
pathogenic microorganisms and also initiates acquired
immune responses. Thus, oral vaccines present an ideal
immunoprophylactic strategy for eliciting protection against
this type of infection. However, an obstacle in the generation
of oral vaccine formulations is maintaining immunogenicity
while simultaneously avoiding being denatured in the pres-
ence of the gastric environment. Therefore, we designed a
delivery system resistant to the gastrointestinal environment
by engineering a L. lactis VP4 expression vector. In this
study, the potential of using L. lactis to express heterologous
rotavirus VP4 protein and its ability to act as an antigen
delivery carrier for oral vaccination were analyzed. The
immunogenicity of the recombinant VP4-expressing L. lactis
was analyzed by oral administration of live bacteria in the
BALB/cmice.OurdataindicatethatoralinoculationofVP4-
expressing L. lactis can induce specic immune responses,
both in the mucosal and systemic immune systems in a
mouse model study, which is useful for the subsequent
evaluation of immune responses with recombinant L. lactis
as a potential rotavirus oral vaccine in pigs.
2.MaterialsandMethods
2.1. Reagents. Rabbit anti-PRV serum, 1:3200 ELISA titer,
was prepared as previously described in our laboratory [8];
MTT [3-(4,5-dimethylthiazol-2-y)-2,5-diphenyltetrazolium
bromide], horseradish peroxidase-(HRP-) conjugated goat
anti-mouse IgA, and HRP-conjugated goat anti-rabbit
I g Gw e r ep u r c h a s e df r o mS i g m a( S t .L o u i s ,M O ) .F I T C -
conjugated goat anti-rabbit IgG was purchased from Beijing
Zhongshan Goldbridge Biotechnology Co. (Beijing, China).
2.2. Plasmids and Bacterial Strains. The lactococcal surface-
expression vector pNZ8112, including the Cm resistance
determinant, repA and repC replication elements, usp45
signal sequence, nisA-promoter, and the cell wall anchor
motif obtained from Streptococcus pyogenes M6 protein,
and the L. lactis strain NZ9000 were kindly provided by
NIZO Food Research (Ede, The Netherlands). The pET-
VP4 recombinant expression plasmid containing porcine
rotavirus VP4 gene was constructed in our laboratory, and
VP4 protein was expressed and puriﬁed as described previ-
ously [8]. JL94 isolates of rotavirus virus were propagated in
MA104 cells (ATCC, Rockville, MD) as described [9].
2.3. Construction of the Lactococcus lactis VP4 Expression
Vector. A 756-bp gene fragment encoding the main
functional antigen regions of the rotavirus VP4 (1–252
amino acids, encompassing the whole VP8 and part of VP5)
was obtained from the recombinant plasmid DNA pET-
VP4 containing the complete VP4 gene using polymerase
chain reaction (PCR) with a speciﬁc forward primer,
5 GACGCAAGCATGGCTTCGCTCATTTATAGACAA3 ,
containing an SphI site (underlined) and a reverse primer,
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Figure 1: Restriction enzyme and PCR analysis of pNZ8112-
VP4. Lane 1, a 756bp VP4 fragment ampliﬁed from recombinant
plasmid DNA pET-VP4; Lane 2, SphIa n dXbaI digestion of the
recombinant expression vector pNZ8112-VP4 showing both vector
and insert; Lane 3, 2000bp DNA ladder.
5 ATTTCTAGAAGCTCTAGAGTGCACTATCTCTCT3 ,con-
taining an XbaI site (underlined). PCR ampliﬁcation
conditions were as follows: 95
◦Cf o r5m i n u t e s ;3 0c y c l e so f
95
◦Cf o r1m i n u t e ;5 5
◦Cf o r1m i n u t e ;7 2
◦Cf o r1m i n u t e ;
and 72
◦C for 10 minutes for the ﬁnal extension. PCR
products were puriﬁed and digested by SphIa n dXbaIa n d
then inserted into the corresponding sites of the pNZ8112
expression vector. Electroporation of Lactococcus lactis was
carried out as previously described [10, 11]. Brieﬂy, 10μL
of pNZ8112-VP4 plasmid DNA was added to 150μLo fL.
lactis strain NZ9000, gently mixed at 4◦Cf o r5m i n u t e s ,
and subjected to a single electric pulse (25μF of 2.5kV/cm).
The mixture was then incubated in M17 medium without
Cm at 30
◦C anaerobically for 2 hours and was then selected
on M17-agar medium containing 10μg/mL of Cm. The
respective NZ9000 transformants containing pNZ8112-VP4
plasmid DNA were extracted and subjected to restriction
enzyme digestion, PCR (Figure 1), and sequencing (data not
shown) was carried out for the identiﬁcation. L. lactis strain
NZ9000 transformed with the pNZ8112-VP4 was designated
pNZ8112-VP4/NZ9000.
2.4. VP4 Protein and Localization Analysis. To analyze
the expression and localization of the VP4 fusion pro-
tein, pNZ8112-VP4/NZ9000 was inoculated in fresh M17
medium with 0.5% glucose at a ratio of 1:250. For the
induction of nisA promoter, nisin was added to a ﬁnal
concentration of 10ng/mL when grown to an optical density
at 600nm of 0.5. Growth was continued for 3 hours until an
optical density at 600nm of 1.0 was reached. Nisin-induced
pNZ8112-VP4/NZ9000 was harvested by centrifugation at
12,000g for 10 minutes at 4◦C .T h eb a c t e r i a lp e l l e t sw e r e
washed twice with sterile 50mM Tris-Cl, pH 8.0, and
incubated with 10mg/mL lysozyme at 37
◦Cf o r6 0m i n u t e s .
Cell lysates were centrifuged at 15,000g for l0 minutes,Journal of Biomedicine and Biotechnology 3
and the supernatant was maintained at −20
◦C for further
analysis. The bacterial protein supernatant was examined
by 12% SDS-PAGE (sodium dodecyl sulfate polyacrylamide
gel electrophoresis) and then electrotransferred onto nitro-
cellulose membrane. Immunoblots were carried out using
rabbit anti-VP4 serum in 10mL at a dilution of 1:1000 with
phosphate-buﬀered saline (PBS) at 37
◦Cf o r6 0m i n u t e sa f t e r
blocking with TBST (Tris-buﬀered saline, 0.05% Tween-20)
buﬀer containing 5% skimmed milk at 4◦C overnight and
washed in PBS three times for 5 minutes between all steps.
Immunoblots were then washed and incubated with 1:2000
dilutionofHRP-conjugatedgoatanti-rabbitIgGin10mLfor
60 minutes. Binding was visualized using Chemiluminescent
Substrate reagent (Pierce) according to the manufacturer’s
instruction.
Immunoﬂuorescence was used to analyze VP4 protein
surface expression by pNZ8112-VP4/NZ9000 as described
previously [12]. Brieﬂy, 2mL of 12-hour nisin-induced
cultures including pNZ8112-VP4/ZN9000 and pNZ8112/
NZ9000 were harvested by centrifugation at 4000g for 10
minutes at 4◦C, respectively, washed with PBS three times by
centrifugation at 4000g for 10 minutes each, resuspended in
1mLsterilePBS3%bovineserumalbumin(BSA)containing
anti-VP4 antibodies, and then incubated for 1 hour at 37
◦C.
The cells were then pelleted and washed three times with
sterile PBS 0.05% Tween 20. The cell-antibody complexes
were then incubated in 2mL of 1:500 dilution of FITC-
conjugated goat anti-mouse IgG containing 1% Evans blue
or of FITC-conjugated goat anti-mouse IgG without 1%
E v a n sb l u eo r1 %E v a n sb l u eo n l yf o r1h o u ra t3 7
◦C in the
dark. Cells were washed three times with PBS 0.05% Tween
20 and streaked onto slides and then air dried on a glass slide
a n dﬁ x e dw i t hc o l da c e t o n ea t−20◦Cf o r3 0m i n u t e s .A n a l y -
sis was performed using a confocal microscope. Noninduced
recombinant strains were used as negative controls.
2.5. Animal Immunizations. Eight-week old female BALB/c
mice weighing 18–20g, purchased from Harbin Veteri-
nary Research Animal Laboratory (Harbin, China), were
used as an animal model for the immune responses to
pNZ8112-VP4/ZN9000 recombinant strain. The mice were
randomly divided into two groups (n = 10) and were
housed under standard conditions with free access to food
and water. pNZ8112-VP4/NZ9000 and pNZ8112/NZ9000
were cultured and centrifuged. Cell pellets were washed
once with sterile PBS and resuspended in PBS (pH 7.4) at
a concentration of 1010 colony-forming units (CFU)/mL.
All of the mice in the two groups orally received a dose
of 109 CFU/mL. The immune protocol was performed
as described previously [13]. Brieﬂy, all the mice were
administered on three consecutive days at days 0, 1, and
2. A booster immunization was administered at days 14,
15, and 16, and a second booster was given at days 28, 29,
and 30.
2.6.ELISAAssays. Mouseserawerecollectedondays0,9,25,
and 41 following the ﬁrst immunization and stored at −20
◦C
until required. Feces were collected on days 0, 1, 7, 14, 17,
21, 24, 29, 31, and 35 after the ﬁrst immunization, and IgA
was extracted as described previously [14, 15]. Ophthalmic
washes were obtained by washing eyes with 50 μL PBS on
days 0, 9, 16, 25, 32, and 35 after the ﬁrst immunization,
and the vagina was washed with 200mL PBS and collected
on the same days as those of the ophthalmic washes. All
of the samples were stored at −20
◦C until required. Before
measurement by indirect ELISA, two identical samples from
the sera, feces, as well as ophthalmic and vaginal washes were
mixed together into one detection well for a total of four
wells representative of eight samples, which were detected
at diﬀerent time points for each group. ELISA plates used
to detect the sIgA levels in feces, ophthalmic and vaginal
washes, and the IgG levels in sera were coated overnight at
4◦C with 200μLo f1 0 6.2 TCID50/0.2mL porcine rotaviruses
propagated on MA104 cells, and the MA104 cell cultures
were used as a negative control. Wells were then washed with
PBS containing 0.05% Tween 20 and blocked with 200μL
of PBS containing 5% skim milk at 37
◦Cf o r2h o u r s .A f t e r
washing, 100μL of fecal extracts, ophthalmic and vaginal
washes, or 100-fold diluted sera samples were added and
used as a primary antibody. After incubation at 37
◦Cf o r1
hour,theplateswerewashedthreetimeswithPBScontaining
1% Tween 20, and 100μL of 1:5000 diluted horseradish
peroxidase-conjugated anti-mouse IgA or goat anti-mouse
IgG was added to every well followed by incubation at 37
◦C
for 1 hour. After washing three times with PBS containing
1% Tween 20, bound antibodies were visualized with 100μL
OPD-H2O2 substrate; the reaction was stopped by addition
of an equal volume of 2N H2SO4, and the optical density
(OD) was measured at 490nm using a microculture plate
reader (ELX800 Bio-Tek Instruments).
2.7. Spleen Cell Proliferation Assay. The proliferation of
mouse spleen cells was examined using the MTT assay.
Spleen cells were isolated and puriﬁed as described [14]a n d
were randomly divided into the control group (RPMI1640
media only), positive control group treated with 5μg/mL of
ConA,lowVP4grouptreatedwith0.5μg/mLofVP4protein,
and high VP4 group treated with 5μg/mL VP4 protein.
The cells were incubated in 5% CO2 at 37
◦C for 72 hours,
and 10μL of 5g/L MTT was added to each well and then
solubilized with 150μL of 30% dimethyl sulfoxide (DMSO)
for10minutesat37
◦C.Theopticaldensity(OD)ofeachwell
was measured at 570nm with an ELISA Reader (Elx800 Bio-
Tek Instruments).
2.8. Determination of Neutralizing Antibodies. Neutraliza-
tion was determined using the microplates [15]. Brieﬂy,
antisera of mice immunized with pNZ8112-VP4/NZ9000
and pNZ8112/NZ9000 were ﬁltersterilized and inactivated at
56◦C for 30 minutes and serially diluted at 2-fold increments
from 1:5 to 1:640 by mixing 100μL of serum with 100μLo f
Eagle’s medium containing 100 TCID50 of porcine rotavirus.
The virus-serum mixture was incubated at 37
◦Ci na n
atmosphere of 5% CO2 for 1hour. Each diluted serum
sample was tested in four replicate wells. The OD value of
virus-induced cytotoxicity was measured at 96 hours after4 Journal of Biomedicine and Biotechnology
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Figure 2: SDS-PAGE and western blot analysis. Total cell
lysates were analyzed by SDS-PAGE and western blot. Coomassie
blue gel staining shows the expression of a 27KD protein in
pNZ8112-VP4/NZ9000 induced by nisin (lane 2, as arrow indi-
cates the VP4 protein), and no corresponding protein in non-
nisin induced pNZ8112-VP4/NZ9000 (lane 3) and nisin-induced
pNZ8112/NZ9000 (lane 4) can be seen. Similar results were
observed by western blot. Nisin-induced pNZ8112-VP4/NZ9000
(lane 5), non-nisin-induced pNZ8112-VP4/NZ9000 (lane 6), and
nisin-inducedpNZ8112/NZ9000(lane7),lane1,ProteinMolecular
Marker.
infection at 490nm using the CytoTox 96 nonradioactive
cytotoxicity assay (Promega) according to the instruction
of the manufacturer, and neutralization titers were also
examined for cytopathic eﬀects (CPEs) under a microscope.
3. Results
3.1. Target Protein Identiﬁcation. The cell lysates from nisin-
induced pNZ8112-VP4/NZ9000, pNZ8112-VP4/NZ9000,
and noninduced pNZ8112-VP4/NZ9000 were analyzed by
SDS-PAGE and western blotting using anti-VP4 serum of
porcine rotavirus. Coomassie blue gel staining revealed
an approximately 27kDa band in induced pNZ8112-
VP4/NZ9000 (Figure 2, lane 2) but not in non-nisin-
induced pNZ8112-VP4/NZ9000 (Figure 2,l a n e3 )o r
in pNZ8112/NZ9000 (Figure 2, lane 4). Similarly, an
immunoreactive band was detected via western blot in a
similar position as observed in the SDS-PAGE in induced
pPNZ8112-VP4/NZ9000 (Figure 2, lane 5). As the negative
control, the non-nisin-induced recombinant strain of
pNZ8112-VP4/ZN9000 (Figure 2, lane 6) and induced
pNZ8112/ZN9000 (Figure 2, lane 7) did not display the
corresponding immunoreactive band. These results show
that the nisin promoter from pNZ8112 could eﬃciently
induce the expression of heterologous protein.
The immunoﬂuorescence assay also conﬁrmed the
expression of VP4 protein. There was green-yellow or green
ﬂuorescence on the cell surface of nisin-induced pNZ8112-
VP4/NZ9000 when incubated either with FITC-conjugated
goat anti-mouse IgG containing 1% Evans blue (Figure 3(a))
or FITC-conjugated goat anti-mouse IgG (Figure 3(c)).
Similarly, there was no green ﬂuorescence in non-nisin-
induced pNZ8112-VP4/NZ9000 (Figure 3(d)). There was
no green ﬂuorescence on the cell surface of nisin-induced
pNZ8112/NZ9000, and the pellets was dyed red by Evans
blue (Figure 3(b)). The localization analysis resultssuggested
that VP4 protein could be exposed on the outer side of the
cell wall. It could not be detected in the supernate of induced
cultures of pNZ8112-VP4/NZ9000, even after concentrating
50-fold using a Millipore Ultrafree-15 column (data not
shown).
3.2. Anti-VP4 Responses Following Immunization. BALB/c
micewereusedasmodelanimalsforinvestigatingthespeciﬁc
immune responses to a recombinant strain expressing VP4
antigen, and speciﬁc sIgA or IgG against porcine rotavirus
VP4 were detected by indirect ELISA. To evaluate the levels
in the local and systemic mucosal immune system, all mice
were immunized via oral route. The results showed that
there was no substantial diﬀerence in antibody titers both
in sIgA and IgG between the pNZ8112-VP4/NZ9000 and
pNZ8112/NZ9000 groups prior to immunization. Antigen-
speciﬁc antibodies could be detected in the sera at day 9
following the ﬁrst immunization. After the ﬁrst booster, a
high level of serum antibodies against porcine rotavirus VP4
occurred in the nisin-induced pNZ8112-VP4/NZ9000 group
comparedwiththepNZ8112/NZ9000group,andthespeciﬁc
antibody levels did not seem to increase much after a second
booster when compared to the ﬁrst booster; however, the
levels remained high (Figure 4). Mucosal antibody sIgA was
evaluated in feces (Figure 5(a)) and vaginal (Figure 5(b))
and ophthalmic washes (Figure 5(c)) in orally immunized
mice. The results revealed an apparent increase in sIgA titers
in these diﬀerent samples at days 7–9 after the primary
immunization. The higher anti-VP4 sIgA was obtained
following the booster series, but a second booster did not
raise the sIgA titers much higher than the ﬁrst booster. These
results indicate that a local and systemic mucosal sIgA and
serum IgG response can be produced in mice immunized via
the oral route.
3.3. Proliferation Assay. To explore the speciﬁc cellular
immune responses of mice immunized with pNZ8112-
VP4/NZ9000 against porcine rotavirus VP4, spleen cells
from pNZ8112-VP4/NZ9000 and pNZ8112/NZ9000 groups
following three immunizations were isolated and stimulated
withpuriﬁedporcinerotavirusVP4proteinatdiﬀerentdoses
invitro.Proliferationofmurinelymphocyteswasdetectedby
theMTTassay.SpleniccellsfromthepNZ8112-VP4/NZ9000
group signiﬁcantly increased following speciﬁc stimulation
with puriﬁed VP4 protein compared to the proliferation of
spleen cells harvested from control mice (Table 1, P<. 05).
3.4. Neutralizing Ability of Porcine Rotavirus Infection in
MA104 Cells. To check the neutralizing ability of porcine
rotavirus infection in MA104 cells, serum samples obtained
from mice immunized with pNZ8112-VP4/NZ9000 and
pNZ8112/NZ9000 were incubated with porcine rotavirus
at a dose of 100 TCID50 for 1 hour at 37
◦Ci nv i t r oa n d
then used to infect MA104 cells. As shown in Figure 6,
antiserum immunized with pNZ8112-VP4/NZ9000 inhib-
ited cytopathicity in a dose-dependent manner. In contrast,Journal of Biomedicine and Biotechnology 5
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Figure 3:CellsurfaceexpressionofVP4.Nisin-inducedpNZ8112-VP4/NZ9000showedspeciﬁcgreenﬂuorescencewhenstainedeitherwith
FITC-conjugated goat anti-mouse IgG containing 1% Evans blue dye (a) or FITC-conjugated goat anti-mouse IgG without Evans blue dye
(c). No green ﬂuorescence was observed, but red pellets can be seen in induced pNZ8112-VP4/NZ9000 (d) stained with 1% Evans blue and
in pNZ8112-/NZ9000 stained with FITC-conjugated goat anti-mouse IgG containing 1% Evans (b).
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Figure 4:Speciﬁcanti-VP4IgGinserumresponseafteroralimmu-
nization. Mice were orally immunized with 109 CFU of pNZ8112-
VP4/NZ9000 and pNZ8112-VP4/NZ9000, and the immune proto-
col was administered on three consecutive days: the inoculation at
days 0, 1, and 2; a booster at days 14, 15, and 16; a second booster
at days 28, 29, and 30. Mice sera were collected on days 0, 9, 25, and
41 following the ﬁrst immunization. Sera samples were analyzed
for the presence of IgG-speciﬁc VP4 antibodies by ELISA. The OD
value of each well represents a mixture of two serum samples; the
bars represent IgG mean OD values in four wells representative of
eight samples, which were detected at diﬀerent time points for each
group.
the control serum immunized with pNZ8112/NZ9000 could
notinhibitvirus-inducedcytopathicity,andaserumneutral-
ization titer of 1:40 of pNZ8112-VP4/NZ9000-immunized
mice could be determined according to the cytopathic eﬀect
(CPE) on MA104 cells infected with porcine rotaviruses.
4. Discussion
Many lactic acid bacteria (LAB) vectors used to express
and deliver heterologous pathogen antigens have been
constructed in recent years [16–19]. The discovery of such
Table 1: Spleen cell proliferation to VP4 in immunized micea.
Antigen dose
(μg/mL)
pNZ8112b pNZ8112-VP4c
0.5 0.036d ±0.002 0.087d ±0.003
5.0 0.058d ±0.001 0.971d ±0.003
Positive control
(5μg/mL Con A)
0.871±0.003 0.822±0.002
Control group
(RPMI 1640)
0.031±0.002 0.026±0.002
an = 10.
bSpleen cell proliferation from mice immunized with L. lactis harboring the
pNZ8112 plasmid.
cSpleen cell proliferation from mice immunized with L. lactis harboring the
pNZ8112-VP4 plasmid.
dP <. 05 versus control (t-test).
vectors oﬀers a new way to explore live bacterial vehicle
vaccines for the prevention of infectious diseases, especially
inmucosalinfectiousdiseases.Inthispaper,weconstructeda
surface-expression recombinant L. lactis pNZ-VP4/NZ9000,
and VP4 expression was conﬁrmed by SDS-PAGE, West-
ern blot analysis, and immunostaining. Balb/c mice were
immunized orally with recombinant L. lactis expressing VP4,
and cellular, mucosal, and systemic immune responses were
examined. We found that VP4-expressing recombinant L.
lactis induced both local and systemic humoral and cellular
immune responses against the VP4 rotavirus while using
mice as model animals.
Group A rotaviruses, the main agents associated with
signiﬁcant diarrheal disease in humans and animals, are
nonenveloped viruses containing 11 RNA fragments. Outer
capsidproteinsareofimportanceininfectionandimmunity.
VP4, a nonglycosylated outer capsid protein [20], has been
implicated as a virulence determinant in mice and piglets
[21]. VP4 also induces neutralizing antibodies [22, 23], and
antibodies directed against VP4 neutralize the virus in vitro
[24, 25] and passively protect mice against heterologous
rotavirus challenge in vivo [26]. Further studies have shown
that VP4 eﬀectively induces protective immunity in animals6 Journal of Biomedicine and Biotechnology
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Figure 5: Anti-VP4-speciﬁc IgA responses. Speciﬁc anti-VP4
IgA was measured in fecal (a), vaginal washes (b), or lacrimal
ﬂuids (c). Mice were orally immunized with 109 CFU of
pNZ8112-VP4/NZ9000 and pNZ8112-VP4/NZ9000, respectively.
The immune protocol was administered on three consecutive days:
immunization at days 0, 1, and 2; a booster at days 14, 15, and 16;
and a second booster at days 28, 29, and 30 (the arrows on the X-
axis indicate the times of vaccination and boosters). Samples from
fecal extracts, vaginal washes, and lacrimal ﬂuids were analyzed for
the presence of speciﬁc Anti-VP4 IgA by ELISA. The OD value of
each replicate well is the one of the mixture of two samples; the
bars represent IgA mean OD values in four wells representative of
eight samples, which were detected at diﬀerent time points for each
group.
[27, 28]. Proteolytic cleavage of VP4 into VP5 and VP8
results in an enhancement of viral infectivity [29, 30]. DNA
vaccines encoding the murine rotavirus proteins VP4, VP6,
or VP7 can induce rotavirus-speciﬁc serum antibodies and
virus-speciﬁccytotoxicTlymphocyteresponsesgeneratedby
each of the three vaccines, but virus-neutralizing antibodies
could be detected only in mice that were inoculated with
DNA vaccines encoding for VP4 and VP7 [31]. VP6 DNA
vaccine did not provide signiﬁcant protection against a
rotavirus challenge [32]. Therefore, the VP4 protein plays a
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Figure 6:MA104cellswereinfectedwithporcinerotaviruses(PRV)
at a dose of 100 TCID50 in the presence of serial dilutions of anti-
PRV antiserum or a negative serum. Anti-PRV antibodies inhibited
cytopathicity in a dose-dependent manner. In contrast, the control
serum could not inhibit virus induced cytopathicity.
major role in porcine rotavirus immune prophylaxis. Since
the VP4 protein is associated with protective immunity, we
used it as a target antigen to evaluate its immunogenicity as
a potential mucosal vaccine.
Mucosalimmunityistheﬁrstbarrierinthepreventionof
infections beginning via the mouth, respiratory, and genital
tracts. Stimulation of mucosal immunity is most eﬃciently
induced following oral immunization, as it stimulates the
production of sIgA and elicits systemic immunity. However,
one obstacle in the development of eﬀective oral vaccines is
that target antigens are often unable to withstand denaturing
in the environment of the stomach and intestinal tract
before reaching the surface of the intestinal mucosa and
eﬀectively stimulating gut-associated lymphatic tissue. One
strategy that can be used to overcome this is to develop
a live expression vector that can both properly deliver and
express the heterogenic antigen and survive in the intestinal
milieu [17, 18]. We investigated the potential adhesion and
persistence of cFDA-SE-labeled L. lactis NZ9000 orally fed
to mice in the intestines. At day 7 following inoculation,
the amounts of L. lactis NZ9000 that remained adherent
to the intestinal mucosa were 69.76%, 51.59%, and 60.67%
of those on the ﬁrst day in the duodenum, jejunum, and
ileum,respectively(datanotshown).Lactococcusprovidesan
excellent expression system, because it is safe and can persist
in the intestinal mucosa. In addition, the long-term use of
Lactococcus in the food industry supports the beneﬁcial use
of these kinds of organisms. L. lactis is one of the primarily
utilized species in the food industry, in fermentation and
in medicine. L. lactis grows rapidly and can be processed
easily, making it an ideal expression vector for exogenous
gene products [33–35].
Some recombinant lactobacilli expressing heterologous
pathogen antigens have been constructed, such as Strepto-
coccus pneumoniae antigens PsaA and PspA, cholera toxin B
subunit, and transmissible gastroentritis coronavirus spike
glycoprotein [36–38]. These organisms have been shown
to be good live vehicles for the delivery of antigens forJournal of Biomedicine and Biotechnology 7
mucosal immunization. Currently, our research is under
way to determine whether the recombinant Lactococcus lactis
expressing porcine rotavirus VP4 protein could be used
to stimulate mucosal and systemic immunization and to
produce the protective anti-VP4 antibodies after mucosal
vaccination in porcine model. Serial dilutions of the antisera
ofmiceimmunizedwithpNZ8112-VP4/NZ9000andcontrol
sera immunized with pNZ8112/NZ9000 were mixed with an
equal volume of 100 TCID50 r o t a v i r u sa t3 7
◦Cf o r1h o u r ,
respectively, and MA104 cells were then infected with the
virus-serum mixture. Cytopathicity was strongly inhibited
by the addition of the antiserum of mice immunized with
pNZ8112-VP4/NZ9000 in a dose-dependent manner. In
contrast, the control sera could not inhibit virus-induced
cytopathicity, indicating that the protective antigen-speciﬁc
antibody responses in sera from the mice immunized orally
were generated by our intervention.
IgA is the predominant antibody at the mucosal sur-
face, as it is locally produced at a level that exceeds
that of all of other immunoglobulins [39, 40]. Therefore,
an oral porcine rotavirus vaccine must induce a speciﬁc
mucosal IgA response. We used BALB/c mice as an animal
model and evaluated the immunogenicity of VP4-expressed
recombinant L. lactis following oral administration. Mucosal
antibody secretory IgA (sIgA) was detected in feces vaginal
and ophthalmic washes. Speciﬁc anti-VP4 sIgA can be
o b t a i n e di nf e c e sv i at h eo r a lr o u t ea sw e l la si nv a g i n a la n d
ophthalmic washes, indicating that VP4-expressed recom-
binant L. lactis is able to elicit both local and systemic
mucosal immune responses, which is important for speciﬁc
resistance to respiratory and genital tract infectious diseases
but not intestinal infectious diseases. From our experiments
investigating the detection of mucosal sIgA and serum IgG
after a prime vaccination, a booster at a two-week interval
apparently increased the production of anti-VP4 sIgA, but
a second booster did not seem to increase the sIgA titer
much higher than that of the ﬁrst booster. These results
indicate a more rational vaccination procedure that would
need to be administered to obtain a satisfactory antibody
response. An oral administration regime was used in this
study, which consisted of three sets of three successive
daily doses of the VP4-expression recombinant L. lactis as
the experimental vaccine. This protocol was adapted from
the procedure of Challacombe [13], who found that this
pattern of immunization was consistently eﬀective when
particulate oral vaccines were used to immunize mice.
Whether this procedure is suitable for L. lactis expression
in mice immunization needs to be further tested in future
experiments.
Splenic cellular proliferation assay also supports the
speciﬁc immune responses by immunogen VP4 induction.
Following three vaccinations with VP4-expressed L. lacti
in vivo, the activated lymphocytes were reexposed to the
speciﬁc puriﬁed VP4 antigen and were then stimulated to
initiate metabolizing cells, which can be detected with MTT.
The results showed that splenic cells from the pNZ8112-
VP4/NZ9000 group signiﬁcantly increased following speciﬁc
stimulation with puriﬁed VP4 protein compared to the
proliferation of spleen cells harvested from control mice.
Many questions relevant for a good mucosal vac-
cine using the L. lactis recombinant strain of pNZ8112-
VP4/NZ9000 remain to be investigated in the near future,
such as dosage of inoculation, level of expression for the
target antigen, optimal time of administration, and the
reactivity of diﬀerent animals. This is only a preliminary
study using mice as model animals, and thus it is necessary
to further investigate the immunogenicity and immunopro-
tection of porcine rotavirus VP4-expressed recombinant L.
lactis in pigs.
The data presented in this report demonstrated that the
use of L. lactis as an expression vector for the rotavirus
VP4 surface antigen was safe and eﬀective following oral
vaccination in mice. The mice after administration are all
in good condition. None of the mice exhibited any ill
eﬀects or died. Oral immunization elicited speciﬁc cellular
and humoral immunity, including anti-VP4 sIgA, which is
important for the development of a potential oral vaccine
against porcine rotavirus infection initiated at mucosal
surfaces. Future experiments will focus on testing VP4-
expressed recombinant L. lactis vaccine in a porcine model
of the disease as a means of establishing the formulation’s
eﬀectiveness against infections in its natural host. Neverthe-
less,givenitsprobioticeﬀectsandharmlessnature,lacticacid
bacteria would make a very appropriate oral vaccine carrier
to delivery heterologous antigens.
5. Conclusions
In this report, we found that using L. lactis as an expression
vector for rotavirus VP4 surface antigen was safe and
eﬀective following oral vaccination in mice. Oral immu-
nization elicited speciﬁc cellular and humoral immunity,
including anti-VP4 sIgA. The protective antigen-speciﬁc
antibody responses in sera from the mice immunized orally
were generated by the neutralization assay in MA104 cells
infected with porcine rotavirus, which is important in the
control of infections initiated at mucosal surfaces. Future
studies designed to evaluate the eﬃcacy of VP4-expressed
recombinant L. lactis in pigs are needed.
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